Le Lézard
Classified in: Health
Subject: MIN

Are You Feeding Your Prostate Cancer?


MARINA DEL REY, Calif., Sept. 21, 2020 /PRNewswire/ -- While this September may feel different than years past, it is just as important to stay connected and proactive with your prostate health. This year, Prostate Oncology Specialists encourages men to focus on their prostate health by improving their diet and consuming updated, accurate information.     

Men with prostate cancer need the right diet and a consistent exercise routine to help them manage their weight. Studies show that overweight men often have worse prostate cancer outcomes, including higher mortality rates and more advanced prostate cancer. But what type of diet is best for men with prostate cancer? Advanced imaging studies show that prostate cancer feeds on proteins and amino acids, both components of animal products. A plant-based diet will help men starve their prostate cancer and stay proactive in their prostate health.  

Beyond proteins and fats, prostate cancer also feeds on fear and misinformation. Many men base treatment decisions in fear instead of fact. Rushing into a treatment decision and relying only on partial information may lead to irreversible side effects and regret. Patient empowerment is the key to better outcomes. This September, listen to the PROSTATE PROS podcast feed and empower yourself with your prostate cancer options. Explore topics like: Are supplements really worth it? Can drugs from other cancers be helpful for men with prostate cancer? Should you check out genetic testing?

Dr. Mark Scholz, Medical Director of Prostate Oncology Specialists, says: "Prostate Cancer Awareness Month provides a unique opportunity to engage in conversation. A lot of patient education happens inside a doctor's office, but with office visits being postponed during the pandemic, many men are missing out on important and updated information about prostate cancer screening and treatment options. Creating content and connecting with community that extend outside of the office walls are crucial for continued patient education and empowerment." 

Now in its second season, PROSTATE PROS is a convenient way to get updated, non-biased information between appointments and stay connected to prostate news while social distancing. Make informed decisions about your health on your own schedule.    

Episodes are released the first Monday of each month and are 15-20 minutes in length. Explore PROSTATE PROS at podcast.prostateoncology.com and listen on Apple Podcasts, SoundCloud, or Google Podcasts.

Join the conversation and help spread the word about screening and treatment options. Follow Prostate Oncology Specialists on twitter @keepprostate or email PROSTATE PROS at [email protected]

SOURCE Prostate Oncology Specialists


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: